logo
  

AutoNation Bottom Line Retreats In Q1, But Beats Estimates; To Buy Back Up To Addl. $1 Bln Shares

(Adds Share buyback)

AutoNation Inc. (AN) revealed a profit for first quarter that decreased from the same period last year but beat the Street estimates.

The company's earnings totaled $190.1 million, or $4.49 per share. This compares with $288.7 million, or $6.07 per share, in last year's first quarter.

Analysts on average had expected the company to earn $4.27 per share, according to figures compiled by Thomson Reuters. Analysts' estimates typically exclude special items.

The company's revenue for the quarter rose 1.4% to $6.49 billion from $6.40 billion last year.

Share repurchase

AutoNation announced that the Board of Directors authorized the repurchase of up to an additional $1.0 billion of common stock under its share repurchase program. The firm currently has approximately $1.1 billion under the program.

For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Retail giant Walmart reported Thursday a profit for the first quarter that soared from last year, reflecting higher gross margins and strong growth across all its operating segments. Both adjusted earnings per share and quarterly revenues topped analysts' expectations. While reporting financial results for the first quarter on Thursday, retail giant Walmart, Inc. (WMT) initiated its adjusted earnings and net sales growth guidance for the second quarter, well above analysts' estimates. It also maintained full-year 2025 outlook. For the second quarter, the company... Shares of Siemens AG were declining around 5 percent in German trading after the conglomerate reported Thursday weak profit in its second quarter on the absence of prior year's hefty gain as well as lower revenues. Orders also were lower in the quarter. Further, the firm confirmed its fiscal 2024 outlook, but trimmed outlook for Digital Industries comparable revenue and margin.

This week, we bring a mix of medical breakthroughs and setbacks. Lyko's MDMA therapy could become the first FDA-approved psychedelic treatment if all goes well as planned. A tragic loss occurred in Pfizer's Duchenne trial and a new study has raised concerns about ultra-processed foods. Find out why Long Beach declared a public health emergency and how Novavax's actions signal optimism.

View More Videos
Follow RTT